

Siegfried to acquire high-quality small molecules drug substance capacity in the US

Zofingen, January 2026

**expect
more**



Disclaimer

This presentation may contain confidential and proprietary information. Any use of the presentation or the information therein without specific permission of Siegfried is prohibited.


No representations or warranties of any kind are made with regard to the accuracy or completeness of the information provided in or in connection with this presentation. Any statements, estimates and projections with respect to Siegfried's anticipated future business or performance were prepared based on assumptions and information available at the time this presentation was prepared.

Siegfried does not assume any liability or responsibility for actions or decisions of third parties based on this presentation.

Siegfried to acquire high-quality small molecules drug substance capacity in the US


Another Siegfried deal: Compelling manufacturing capacity at an attractive price

- Siegfried signed binding agreements to acquire small molecules drug substances sites in the US and Australia
- Transaction adds highly demanded **US-based manufacturing capacity** and strengthens Siegfried's position in key growth segments
- Given Siegfried's strong balance sheet, the acquisition will be financed through existing and new debt instruments
- **Value accretive** acquisition advances EVOLVE+ strategy and supports **long-term profitable growth in the largest pharmaceutical market**



Structurally high demand meets limited US capacities

Significant demand from small and large pharma companies for manufacturing capacity for innovative products



Acquired business includes three high-quality drug substances sites

A perfect fit into our existing global network

Noramco – Wilmington, DE (US)



- Focused on three product families
 - Addiction treatment and prevention
 - ADHD
 - Pain management
- Approx. 185 FTEs

High-quality, multi-purpose site with 150m³ reactor capacity

Purisys – Athens, GA (US)



- CDMO facility for product development, clinical and small-scale manufacturing
- Focused on highly regulated compounds and niche products
- Approx. 45 FTEs

Complementary to Grafton, further expands Acceleration Hub

Extractas Bioscience – Tasmania, (AU)



- Leading manufacturer of purified products
- Approx. 170 FTEs

Backward integration increases resilience of supply chain

Acquisition significantly strengthens our footprint in the US

Exceptional US-based capacity further enhances our customer offering

Comprehensive drug substances offering



Wilmington and Pennsville


- Complementary pharma manufacturing cluster due to proximity and product portfolio
- Controlled substances footprint to be optimized across the two sites
- Wilmington to be repurposed for innovative products



Athens and Grafton

- To form best-in-class Acceleration Hub
- Comprehensive offering for early phase development
- Filling the pipeline for innovative products


US footprint passes critical size: 5 sites and 700 employees



Attractive valuation, well below recent expectations for US assets

Continuation of our highly selective, disciplined and value-accretive M&A

Valuation (EV/EBITDA)



Transaction

- Valuation of acquired business is **below 10 times Enterprise Value / EBITDA**, below our own trading multiple and substantially below seller expectations of trading multiples of other US based assets
- Acquired business will not be dilutive to existing business
- Subject to customary closing conditions, we expect a closing later in the year
- Given Siegfried's strong balance sheet, the acquisition will be financed through existing and new debt instruments

Paving the way for continued, long-term profitable growth across all levels

A decisive step in the execution of our strategy EVOLVE+

Transaction further accelerates profitable growth

EVOLVE+



Broaden our technological offering

Advanced production technologies

Bridging technologies

Aseptic technologies

Grow existing core

Small molecules (DS and DP)

End-to-end offering of DS and DP

Oral/inhalation solid dosage forms

Aseptic liquid dosage forms

Grow the network in US and Europe

Enter and grow new areas

DS antibodies

Cell & gene therapy (CGT)

Viral vectors

Synthetic biology

Data analytics

**Commercial
Excellence**



**Development
Excellence**



**Operational
Excellence**



Thank you for your attention

